Xuzhou Dazhixianxian Trading Co., Ltd. – Trademark Portfolio

Entity Type: 99

Xuzhou Dazhixianxian Trading Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include BONOMO and JUBAOPEN. The owner is based in Xuzhou, Jiangsu.

No. 201, Fuqian Road

Tangzhang Town, Tongshan District

Xuzhou, Jiangsu 221100 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BONOMO
BONOMO
Registered 2024
JUBAOPEN
JUBAOPEN
Registered 2023

Trademark Classifications

Xuzhou Dazhixianxian Trading Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Xuzhou Dazhixianxian Trading Co., Ltd. have?

Xuzhou Dazhixianxian Trading Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Xuzhou Dazhixianxian Trading Co., Ltd. file in?

Xuzhou Dazhixianxian Trading Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Xuzhou Dazhixianxian Trading Co., Ltd.'s most well-known trademarks?

Xuzhou Dazhixianxian Trading Co., Ltd.'s registered trademark portfolio includes well-known marks such as BONOMO and JUBAOPEN. These are among 2 currently registered trademarks in the portfolio.

What is Xuzhou Dazhixianxian Trading Co., Ltd.'s trademark registration success rate?

Xuzhou Dazhixianxian Trading Co., Ltd. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.